Growth Metrics

Merck (MRK) Liabilities and Shareholders Equity (2016 - 2026)

Merck has reported Liabilities and Shareholders Equity over the past 18 years, most recently at $128.7 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 11.78% to $128.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $512.6 billion through Mar 2026, up 10.86% year-over-year, with the annual reading at $136.9 billion for FY2025, 16.87% up from the prior year.
  • Liabilities and Shareholders Equity was $128.7 billion for Q1 2026 at Merck, down from $136.9 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $136.9 billion in Q4 2025 and troughed at $104.5 billion in Q2 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $109.2 billion (2022), against an average of $113.9 billion.
  • Year-over-year, Liabilities and Shareholders Equity increased 18.09% in 2022 and then dropped 2.45% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $109.2 billion in 2022, then dropped by 2.28% to $106.7 billion in 2023, then grew by 9.78% to $117.1 billion in 2024, then grew by 16.87% to $136.9 billion in 2025, then decreased by 5.98% to $128.7 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Liabilities and Shareholders Equity are $128.7 billion (Q1 2026), $136.9 billion (Q4 2025), and $129.5 billion (Q3 2025).